In vitro activity of clindamycin, doxycycline, and trimethoprim/sulfamethoxazole against clinical isolates of ß-hemolytic Streptococcus spp. via BD Phoenix and broth microdilution.
Antimicrob Steward Healthc Epidemiol
; 3(1): e238, 2023.
Article
in En
| MEDLINE
| ID: mdl-38156228
ABSTRACT
We tested 85 isolates of ß-hemolytic Streptococcus spp. against trimethoprim/sulfamethoxazole (TMP/SMX), clindamycin, and doxycycline by broth microdilution (BMD) and BD Phoenix. Susceptibility rates via BMD for TMP/SMX, clindamycin, and doxycycline were 100%, 85.5%, and 56.6%, respectively. TMP/SMX is a potential monotherapy agent for ß-hemolytic Streptococcus skin and soft tissue infections.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Antimicrob Steward Healthc Epidemiol
Year:
2023
Document type:
Article
Affiliation country:
United States